Healthcare / BiotechnologyBSE
$196.95
+2.30 (+1.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $1.5B · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$30.9B
P/E
31.6x
↑EV/EBITDA
8.7x
↓ROE
1.5%
↑Gross Margin
86.1%
↑Debt/Equity
0.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+8.2%
FCF CAGR
—
FCF margin
7.7%
FCF / Net income
2.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $29.32B · net income $974.5M · FCF $2.25B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $29.32B | $29.32B | $27.11B | $25.44B | $23.15B |
| Net Income | $974.5M | $974.5M | $32.4M | $-1.53B | $-298.0M |
| EBITDA | $6.18B | $6.18B | $4.73B | $3.02B | $3.01B |
| EPS | — | — | 0.21 | -9.79 | -1.90 |
| Gross Margin | 86.1% | 86.1% | 81.5% | 76.0% | 76.9% |
| Operating Margin | 7.7% | 7.7% | 6.5% | -1.6% | 4.6% |
| Net Margin | 3.3% | 3.3% | 0.1% | -6.0% | -1.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.46 | 0.46 | 0.41 | 0.41 | 0.38 |
| Current Ratio | 1.23 | 1.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.25B | $2.25B | $1.55B | $761.8M | $-3.54B |
| Returns | |||||
| ROE | 1.5% | 1.5% | 0.1% | -2.7% | -0.5% |
| Valuation | |||||
| P/E | 31.61 | 31.61 | 993.33 | — | — |
| EV/EBITDA | 8.70 | 8.70 | 11.15 | 19.58 | 13.89 |
| P/B | 0.46 | 0.46 | 0.55 | 0.69 | 0.36 |
| Growth & Yield | |||||
| Revenue Growth | 8.1% | 8.1% | 6.6% | 9.9% | — |
| EPS Growth | — | — | 102.1% | -415.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.9%
Start / end P/E
n/dx → n/dx
EPS bridge
0.21 → n/d
Residual
-21.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.